Tacrolimus and Yervoy drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tacrolimus (tacrolimus) and Yervoy (ipilimumab). Common drug interactions include disease progression among females and coagulopathy among males.

The phase IV clinical study analyzes what interactions people have when they take Tacrolimus and Yervoy. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,160 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Yervoy?

Yervoy has active ingredients of ipilimumab. eHealthMe is studying from 26,662 Yervoy users. Check the latest studies of Yervoy.

On Jul, 12, 2026

15 people who take Tacrolimus and Yervoy together, and have interactions are studied.

Tacrolimus and Yervoy drug interactions.

What are the common drug interactions of Tacrolimus and Yervoy, by gender? *:

female:

Disease progression
Malignant neoplasm progression (cancer tumour came back)
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Fatigue (feeling of tiredness)
Malignant melanoma (skin cancer rises from melancytes)
Neurofibrosarcoma (cancerous nerve sheath tumour)
Renal impairment (severely reduced kidney function)

male:

Coagulopathy (blood's ability to clot is impaired)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Lung disorder (lung disease)
Malignant neoplasm progression (cancer tumour came back)
Non-small cell lung cancer (type of epithelial lung cancer)

What are the common drug interactions of Tacrolimus and Yervoy, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Fatigue (feeling of tiredness)
Non-small cell lung cancer (type of epithelial lung cancer)
Malignant melanoma (skin cancer rises from melancytes)
Neurofibrosarcoma (cancerous nerve sheath tumour)
Renal impairment (severely reduced kidney function)
Disease progression
Malignant neoplasm progression (cancer tumour came back)
Coagulopathy (blood's ability to clot is impaired)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)

What are the existing conditions these people have? *

Neurofibrosarcoma (cancerous nerve sheath tumour): 11 people, 73.33%
Malignant Melanoma (skin cancer rises from melancytes): 11 people, 73.33%
Immunodeficiency Disorders: 7 people, 46.67%
Disease Progression: 7 people, 46.67%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 3 people, 20.00%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and Yervoy?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously